US FDA Commissioner Califf’s Farewell Visit To Capitol Hill

Robert Califf’s final appearance on Capitol Hill as US FDA commissioner, a 5 December Senate hearing focused on the agency’s food and nutrition functions, was an appropriate coda to his tenure and preview of things to come under the Trump Administration.

Califf and baby formula
The infant formula shortage food safety a larger part of Commissioner Robert Califf's focus after he took over the agency in 2022. • Source: Nielsen Hobbs; the Pink Sheet | Alamy and Shutterstock images
Key Takeaways
  • Robert Califf’s final Capitol Hill appearance focused on food and nutrition, an issue that dominated much of his most recent tenure leading the FDA.
  • The discussion about food industry greed driving chronic illness could signal areas for agreement between Democrats and HHS Secretary nominee Robert F. Kennedy Jr.
  • The conundrum that the FDA allows people to gain weight through poor diet and also approves expensive weight loss treatments likely will remain a theme during the Trump Administration.

A 5 December Senate Health, Education, Labor and Pensions Committee hearing was an appropriate send off for outgoing US Food and Drug Administration Commissioner Robert Califf.

The hearing focused on the FDA’s food and nutrition operations, including the link between packaged foods and public health. The hearing title, courtesy of HELP Committee Chair Bernie Sanders,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

US FDA Meeting Drought Ends … With A Vengeance

 

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

More from Legislation

Korean Pharma Industry Proposes Policies As Election Nears

 
• By 

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.